Patents by Inventor Emil R. Smith

Emil R. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for the treatment of allergic rhinitis
    Patent number: 7214684
    Abstract: Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
    Type: Grant
    Filed: November 17, 2004
    Date of Patent: May 8, 2007
    Assignee: Sepracor Inc.
    Inventors: A. K. Gunnar Aberg, John R. McCullough, Emil R. Smith
  • Compositions of descarboethoxyloratadine
    Patent number: 7214683
    Abstract: Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
    Type: Grant
    Filed: March 16, 1998
    Date of Patent: May 8, 2007
    Assignee: Sepracor Inc.
    Inventors: A. K. Gunnar Aberg, John R. McCullough, Emil R. Smith
  • Methods for treating urticaria using descarboethoxyloratadine
    Patent number: 7211582
    Abstract: Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
    Type: Grant
    Filed: November 23, 1999
    Date of Patent: May 1, 2007
    Assignee: Sepracor Inc.
    Inventors: A. K. Gunnar Aberg, John R. McCullough, Emil R. Smith
  • Methods for treating disorders using descarboethoxyloratadine
    Patent number: 5731319
    Abstract: Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
    Type: Grant
    Filed: January 13, 1997
    Date of Patent: March 24, 1998
    Assignees: Sepracor Inc., University of Massachusetts
    Inventors: A. K. Gunnar Aberg, John R. McCullough, Emil R. Smith
  • Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
    Patent number: 5595997
    Abstract: Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: January 21, 1997
    Assignee: Sepracor Inc.
    Inventors: A. K. Gunnar Aberg, John R. McCullough, Emil R. Smith
  • Primary aminoacylanilides
    Patent number: 4237068
    Abstract: Primary amino acylanilides of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen, methyl, ethyl and propyl, R.sub.2 is selected from the group consisting of methyl, ethyl, chlorine, methoxy and ethoxy, R.sub.3 is selected from the group consisting of hydrogen and methyl, R.sub.4 is selected from the group consisting of hydrogen, methyl, and a C.sub.1 -C.sub.4 alkoxy group, R.sub.6 is selected from the group consisting of methyl, ethyl, chlorine, methoxy and ethoxy, R.sub.7 is hydrogen, methyl or ethyl, R.sub.8 is hydrogen, R.sub.9 is hydrogen, methyl or ethyl, R.sub.10 is hydrogen, and n is 0 or 1, with the provisions that(a) when n is 0, R.sub.8 can also be methyl;(b) when n is 1, and R.sub.7 is hydrogen, and R.sub.9 is hydrogen or methyl, then R.sub.10 can also be methyl;(c) when R.sub.1 is hydrogen, R.sub.2 is methyl, R.sub.3 is hydrogen, R.sub.6 is methyl, R.sub.7 is hydrogen, R.sub.8 is hydrogen, and n is 0, then R.sub.4 can be ethoxy or propoxy only;(d) when R.sub.
    Type: Grant
    Filed: August 1, 1978
    Date of Patent: December 2, 1980
    Assignee: Astra Pharmaceutical Products, Inc.
    Inventors: Robert N. Boyes, Benjamin R. Duce, Emil R. Smith, Eugene W. Byrnes
  • Primary aminoacylanilides, methods of making the same and use as antiarrhythmic drugs
    Patent number: 4218477
    Abstract: Primary amino acylanilides of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen, methyl, ethyl and propyl, R.sub.2 is selected from the group consisting of methyl, ethyl, chlorine, methoxy and ethoxy, R.sub.3 is selected from the group consisting of hydrogen and methyl, R.sub.4 is selected from the group consisting of hydrogen, methyl, and a C.sub.1 -C.sub.4 alkoxy group, R.sub.6 is selected from the group consisting of methyl, ethyl, chlorine, methoxy and ethoxy, R.sub.7 is hydrogen, methyl or ethyl, R.sub.8 is hydrogen, R.sub.9 is hydrogen, methyl or ethyl, R.sub.10 is hydrogen, and n is 0 or 1, with the provisions that(a) when n is 0, R.sub.8 can also be methyl;(b) when n is 1, and R.sub.7 is hydrogen, and R.sub.9 is hydrogen or methyl, then R.sub.10 can also be methyl;(c) when R.sub.1 is hydrogen, R.sub.2 is methyl, R.sub.3 is hydrogen, R.sub.6 is methyl, R.sub.7 is hydrogen, R.sub.8 is hydrogen, and n is 0, then R.sub.4 can be ethoxy or propoxy only;(d) when R.sub.
    Type: Grant
    Filed: January 22, 1976
    Date of Patent: August 19, 1980
    Assignee: Astra Pharmaceutical Products, Inc.
    Inventors: Robert N. Boyes, Benjamin R. Duce, Emil R. Smith, Eugene W. Byrnes